HC Wainwright & Co. Maintains Buy on CymaBay Therapeutics, Raises Price Target to $24
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Ed Arce maintains a Buy rating on CymaBay Therapeutics (NASDAQ:CBAY) and raises the price target from $21 to $24.
November 08, 2023 | 1:24 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
CymaBay Therapeutics' price target has been raised from $21 to $24 by HC Wainwright & Co. The firm maintains a Buy rating on the stock.
The news of a price target increase and maintained Buy rating by a reputable analyst firm like HC Wainwright & Co. is likely to be seen positively by the market. This could lead to an increase in the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100